Peritoneal Cancer
Phase 2 Randomized Open-label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Treatment of Patients with Platinum Resistant Ovarian Cancer (PROC) (PRESERVE-004 MK-3475-E24 GOG-3081)
- Details
ClinicalTrials.gov ID:
NCT05446298
Diagnosis Type:
NA
USOR Number:
- Address
520 Country Club Rd
Eugene, OR 97401
P: (541) 683-5001